Therapeutic or Preventive Procedure
Revolutionizing Drug Discovery: The Evolution from Target-Selective Design to AI-Powered Polypharmacology
Drug Discovery, Target-Selective Design, AI-Enabled Polypharmacology, Machine Learning, Systems Biology, Multi-Target Drugs, Personalized Medicine.
FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer
FDA, Elevar Therapeutics, Hengrui Pharmaceuticals, liver cancer, combination therapy, rejection, clinical trials.
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Bayer’s New Drug Shows Promising Phase III Results for Menopause Symptom Relief
Bayer, Phase III results, menopause symptoms, drug, clinical trial, hot flashes, night sweats, hormone therapy
FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer
FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.
Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma
Bristol Myers, Breyanzi, CAR-T therapy, follicular lymphoma, FDA approval, cancer treatment, immunotherapy.
Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership
Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Bristol Myers’ Breyanzi Approved by FDA for Follicular Lymphoma, Joining Gilead and Novartis in CAR-T Treatment
Bristol Myers, Breyanzi, FDA, follicular lymphoma, CAR-T, Gilead, Novartis, cancer treatment, immunotherapy
Ascendis Hormone Replacement Therapy Faces Setback with FDA Review Extension
Ascendis Pharma, hormone replacement therapy, FDA review, delay, three-month extension.
FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data
FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection